Minimum standards of home care for older people in Red Cross Red Crescent volunteer-based programming in the Europe Zone
Joining efforts to control two trelated global epidemics.
Во Всемирном докладе о наркотиках содержится комплексная информация по положению в области незаконных наркотиков. В нем представлены подробные оценки и тенденци..., относящиеся к производству, незаконному обороту и потреблению на рынках опиума/героина, коки/кокаина, каннабиса и стимуляторов амфетаминового ряда. Масштабы проблемы наркотиков удается ограничивать, но существуют признаки того, что стабилизация, достигнутая за последние несколько лет, может подвергаться риску. Среди этих признаков – расширение культивирования в 2007 году опийного мака и коки, некоторый прирост потребления в развивающихся странах и в определенной степени развитие новых схем незаконного оборота. Также отмечалось обнадеживающее сокращение некоторых из основных потребительских рынков.
more
with special reference to prevention and control of avian influenza
The message contained in this publication is clear: countries need a
public health system that can respond to the deliberate release of
chemical and biological agents. Regrettable though this message may
be, the use of poison gas in the war between Iraq and the Islamic
Republic of Iran in the 19...80s, the recent anthrax incidents in the United
States, and the attack with sarin nerve agent, six years earlier, on the
Tokyo underground, illustrate why it is necessary to prepare.
Russian and Japanese version available:
more
Монографія має за мету ознайомити громадськість із проектом ESPAD – Європейське опитування учнів щодо вживання алкоголю та інших наркотичних речовин (European School Survey Pr...oject on Alcohol and other Drugs) і його реалізацією в Україні. Вона містить інформацію про рівень і структуру куріння, вживання алкоголюта наркотиків серед підлітків, динаміку окремих показників за 1995, 1999, 2003,
2007 роки, аналіз гендерних особливостей, а також дані щодо поінформованості підлітків з питань ВІЛ.
more
HRH SA 2030 | Draft HR Strategy for the Health Sector: 2012/13 – 2016/17 Consultation Document
The review’s objectives are to review progress in TB control with emphasis on DOTS strategy implementation, summarize the experience, lessons learnt and methods of work and to make recommendations for international donors, technical agencies and the Ministry of Health.
Anopheles stephensi is a mosquito species that is capable of transmitting both Plasmodium falciparum and P. vivax malaria parasites. Unlike the other main mosquito vectors of malaria, it thrives in urban and man-made environments. Originally native to parts of South Asia and the Arabian Peninsula, A...n. stephensi has been detected, to date, in 7 countries in the African continent.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more